Unlocking nature’s pharmacy: how tea leaves and marine organisms could help transform breast cancer treatment
October 2, 2025Research and Development King Abdullah University of Science and Technology, Oncology, natural products chemistry, triple-negative breast cancer
Looking beyond synthetic chemistry to unlock powerful, naturally derived medicines Each year, World Breast Cancer Awareness Month serves as a …
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
September 26, 2025Research and Development Dupixent, Regeneron, Sanofi, urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
CSL Behring’s angioedema treatments receives NICE recommendation
September 26, 2025Regulatory Affairs, Research and Development Andembry, CSL Behring, hereditary angioedema
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Behring’s ANDEMBRY (garadacimab) for …
Gilead Foundation awards $6.5m in grants to support STEM education
September 26, 2025Research and Development Funding and Investment, Gilead Sciences, stem
Gilead Sciences has committed over $6.5m in grant funding towards improving science, technology, engineering and maths (STEM) education, the company …
Lilly opens fourth US Gateway Labs site
September 26, 2025Research and Development Eli Lilly, Local Investment, biotech, life sciences
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, expanding its network of shared …
Arkivum and PHARMASEAL partner on trial management platform
September 26, 2025Research and Development Arkivum, PHARMASEAL, Trial Management
Arkivum, a digital archiving and preservation solutions provider, has entered into a collaborative agreement with PHARMASEAL, a software company specialising …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
September 23, 2025Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
September 19, 2025Medical Communications, Research and Development LGC Group, biotech, life sciences, pharma
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of Excellence in Ontario, Canada after …
Crown Bioscience opens new US model development centre
September 19, 2025Medical Communications, Research and Development CRO, biotech, crown bioscience, life sciences
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life Sciences and Japan-based JSR Corporation, …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
September 18, 2025Medical Communications, Research and Development Dermatology, UCB, atopic dermatitis, clinical trial
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults with moderate-to-severe atopic dermatitis (AD). …
electronRx to launch pDx app for remote monitoring of chronic respiratory disease
September 18, 2025Research and Development Asthma & COPD, Devices, devices, electronRx, pDx, respiratory diseases (CRDs)
Digital medicine company electronRx, based in Cambridge, UK, has announced the upcoming launch of pDx, a mobile app designed to …
ProteoNic Biosciences launches platform to enhance cell line productivity
September 17, 2025Research and Development Devices, ProteoNic Biosciences, cell line productivity, gene therapy
ProteoNic Biosciences, a biotech company headquartered in Leiden, Germany has unveiled its latest technology platform, the 2G UNic transposon system, developed …
NeoVac appoints Jan H Egberts as chief executive officer
September 17, 2025Analytical & Laboratory Services, Business Services, Clinical Trial Services, Research and Development Devices, Lipid Nanoparticle Technology, Neovac, mRNA Therapies
NeoVac, a clinical-stage biopharma based in Abingdon, UK, has appointed Jan H Egberts as chief executive officer. The company is …
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
September 12, 2025Innovation Award 2025, PlasmidFactory, cell and gene therapy, medical communications, research and development
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with the Innovation Award 2025 of …
Symeres announces acquisition of DGr Pharma
September 11, 2025Medical Communications, Research and Development DGr Pharma, Symeres, biopharma, contract research
Symeres, a Contract Research, Development and Manufacturing Organization (CRDMO) has acquired DGr Pharma, a drug development-focused consultancy. The acquisition will …
Danny Wolin appointed as KJT’s Senior VP of real-world evidence
September 11, 2025Medical Communications, Research and Development KJT, real-world evidence
Danny Wolin has been appointed as Senior Vice President of Real-World Evidence at KJT. KJT is an evidence-based healthcare consulting …
Brian Adams appointed as Kymera’s CLO and Corporate Secretary
September 11, 2025Kymera, biopharma, corporate, immunology
Brian Adams has been appointed as Kymera Therapeutics’ Chief Legal Officer (CLO) and Corporate Secretary. He will lead Kymera’s legal, …
Sapio Sciences and Ultima Genomics form multi-omics research partnership
September 11, 2025Medical Communications, Research and Development Sapio Sciences, Ultima Genomics, biotech, genomics research
Sapio Sciences and Ultima Genomics have formed a strategic partnership to accelerate genomics research. The collaboration aims to make multi-omics …
Richmond Pharmacology promotes Patrick Ramiah to Director
September 8, 2025Clinical Trial Services, Director of Clinical Project Delivery & Operational Excellence, Richmond Pharmacology, corporate, research and development
Patrick Ramiah has been promoted to Director of Clinical Project Delivery & Operational Excellence at Richmond Pharmacology, effective from 1 …
MultiOmic Health and BIO4 Campus sign collaborative Memorandum of Understanding
September 8, 2025Medical Communications, Research and Development AI, BIO4 Campus, Memorandum of Understanding, MultiOmic Health, biotech
MultiOmic Health (MOH), an artificial intelligence (AI)-enabled precision medicine biotechnology company and BIO4 Campus (BIO4), a biotechnology and life sciences …
Latest content
FibroFind appoints Lee Borthwick as CEO
